Project Grant HT94252410946
- This federal Project Grant award of $794,148.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a research project led by Northwestern University to develop a mouse model to investigate differential response to therapy and mechanisms of recurrence in glioblastoma. The project aims to advance understanding of this aggressive form of brain cancer and explore new therapeutic approaches, with potential to benefit both...
- The federal Project Grant award of $384,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Translational Genomics Research Institute (TGen) located in Phoenix, Arizona. The funding supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The project, titled "SINGLE: SIGNATURE ENABLING GLIOMA ENROLLMENT", will be performed from...
- This $1,599,997.00 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of Illinois aimed at transforming healthcare for military service members, veterans, and the broader public. The research, spanning basic, applied, and translational investigations, focuses on innovative approaches to address critical health challenges across diverse medical domains such as cancer,...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is providing $1,465,443 to the University of Illinois to support research on "The Promise of Epigenetic Therapy for Refractory Testicular Germ Cell Tumors". The award period runs from September 1, 2025 to August 31, 2028. As a leading public research institution, the University of Illinois has extensive experience in executing federal grants and...
- This Project Grant award of $1,594,419.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research by The Regents of the University of California, San Francisco (UCSF) on "Radiopathomic Mapping of Tumor Burden for Personalized Management of IDH-Mutant Glioma." The research aims to develop innovative diagnostic and treatment approaches for a specific type of brain cancer through advanced biomedical investigations. This...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,602,572.00 in funding to the University of Illinois to support research on the role of the novel hexokinase HKDC1 in hepatocellular carcinoma. The award has a performance period from July 15, 2024 to July 14, 2027. The University of Illinois, a major public research university in Chicago, will conduct innovative scientific studies to advance...
- The Defense Health Agency awarded a $159,892 Project Grant to the University of Illinois under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into "Metabolic Vulnerabilities Associated to G12C Inhibitor Resistance" from January 1, 2022 through December 31, 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will...
- The federal Project Grant award of $328,000 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) for the project "INTRACALVARIAL DRUG DELIVERY STRATEGIES INTO SKULL BONE MARROW TO CREATE AN ANTITUMORAL MYELOID CELL IMMUNE RESPONSE TO GLIOBLASTOMA". The funding period runs from July 1, 2025 to June 30, 2027 and supports advanced biomedical research aimed at...
- The Defense Health Agency awarded a $1,398,689 Project Grant to the University of Illinois under the Military Medical Research and Development program (CFDA 12.420) to support research on "Pharmacologic Downregulation of SOX2 to Enhance Efficacy of Anti-AR Therapies in Prostate Cancer". The project aims to investigate methods for improving the effectiveness of anti-androgen therapies for prostate cancer through modulating the SOX2 protein. The award will fund this 3-year research...
- This $1,626,438 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports biomedical research conducted by the University of Texas MD Anderson Cancer Center (MD Anderson) to transform healthcare for military service members, veterans, and the general public. The research project, known as the "MCCAIN/BAYH GLIOBLASTOMA CONSORTIUM", will investigate innovative medical solutions for glioblastoma, an aggressive form of...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $158,254.00 to the University of Illinois to support a research project titled "DUAL CRE/LOX AND LENTIVIRAL CRISPR/CAS9 SYSTEM FOR PRECISE IN VIVO DISSECTION OF GBM AND MICROENVIRONMENT INTERACTION." The project aims to advance scientific understanding and treatment of glioblastoma (GBM) by developing innovative genetic technologies for in vivo dissection of GBM and its tumor microenvironment. The award, which runs from August 15, 2024 to August 14, 2026, will fund the university's research efforts to create and deploy a dual Cre/lox and lentiviral CRISPR/Cas9 system for precise genetic manipulation and analysis of GBM progression and interactions with the surrounding tissue environment. This work supports the program's objectives of transforming healthcare for military service members and the broader public through innovative biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $158.3k | 7/25/24 |